Related Experiment Video
Updated: Jul 28, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Malignancies in Prader-Willi Syndrome: Results From a Large International Cohort and Literature Review
Karlijn Pellikaan1,2,3,4, Naomi Q C Nguyen1, Anna G W Rosenberg1,2,3,4
1Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, University Medical Centre Rotterdam, 3015 GD Rotterdam, The Netherlands.
Insights
Malignancies are rare in Prader-Willi syndrome (PWS) patients. Cancer screening is recommended only when symptoms appear, but obesity in PWS may increase cancer risk, warranting program participation.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Endocrinology
Background:
- Prader-Willi syndrome (PWS) is a complex genetic disorder characterized by hypothalamic dysfunction, neurodevelopmental delay, hypotonia, and hyperphagia, leading to obesity.
- Increased life expectancy in PWS patients raises concerns about age-related diseases, including malignancies.
- The genetic basis of PWS involves the loss of expression of paternally expressed genes on chromosome 15q11.2-q13.
Approach:
- Retrospective analysis of medical records for 706 PWS patients (160 children, 546 adults) to identify malignancy prevalence and risk factors.
- Detailed data collection on malignancy type and associated risk factors.
- Comprehensive literature review to explore the relationship between chromosome 15q11.2-q13 genes and malignancies.
Key Points:
- Seven adult PWS patients (18-55 years) were diagnosed with various malignancies, including leukemia, melanoma, and adenocarcinomas.
- All affected patients possessed a paternal 15q11-13 deletion, suggesting a genetic link.
- Several genes within the 15q11.2-q13 region have been implicated in cancer development.
Conclusions:
- Malignancies are infrequent in the PWS population.
- Cancer screening in PWS patients should be guided by the presence of specific clinical symptoms.
- Encouraging participation in national screening programs is advised due to obesity-related cancer risks common in PWS.
Context:
Prader-Willi syndrome (PWS) is a complex disorder combining hypothalamic dysfunction, neurodevelopmental delay, hypotonia, and hyperphagia with risk of obesity and its complications. PWS is caused by the loss of expression of the PWS critical region, a cluster of paternally expressed genes on chromosome 15q11.2-q13. As life expectancy of patients with PWS increases, age-related diseases like malignancies might pose a new threat to health.
Objective:
To investigate the prevalence and risk factors of malignancies in patients with PWS and to provide clinical recommendations for cancer screening.
Methods:
We included 706 patients with PWS (160 children, 546 adults). We retrospectively collected data from medical records on past or current malignancies, the type of malignancy, and risk factors for malignancy. Additionally, we searched the literature for information about the relationship between genes on chromosome 15q11.2-q13 and malignancies.
Results:
Seven adults (age range, 18-55 years) had been diagnosed with a malignancy (acute lymphoblastic leukemia, intracranial hemangiopericytoma, melanoma, stomach adenocarcinoma, biliary cancer, parotid adenocarcinoma, and colon cancer). All patients with a malignancy had a paternal 15q11-13 deletion. The literature review showed that several genes on chromosome 15q11.2-q13 are related to malignancies.
Conclusion:
Malignancies are rare in patients with PWS. Therefore, screening for malignancies is only indicated when clinically relevant symptoms are present, such as unexplained weight loss, loss of appetite, symptoms suggestive of paraneoplastic syndrome, or localizing symptoms. Given the increased cancer risk associated with obesity, which is common in PWS, participation in national screening programs should be encouraged.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
05:44Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Related Concept Videos
Abnormal Proliferation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...